Dominic Pilon
Montreal
Education
M.Sc. and B.B.A., economics, Université du Québec a Montréal
Summary of Experience
Mr. Pilon specializes in biostatistics and health economics and outcomes research (HEOR). He has conducted and directed numerous studies and analyses for the investigation of topics such as clinical efficacy, cost of illness, cost effectiveness, resource utilization patterns, and treatment patterns in a wide range of therapeutic areas, including major depressive disorders, schizophrenia, oncology, inflammatory bowel diseases, dermatology, respiratory diseases, diabetes, and cardiovascular diseases.
Mr. Pilon has extensive experience performing retrospective insurance claims database analyses, retrospective electronic medical record studies, prospective survey studies, and clinical trial data analyses. He has presented his research at numerous international conferences, including meetings of the American Psychiatric Association (APA) and American Society of Clinical Oncology (ASCO), and published articles in several peer-reviewed journals, including the Journal of Clinical Psychiatry, the Journal of Managed Care & Specialty Pharmacy, Advances in Therapy, Menopause, Clinical Therapeutics, Current Medical Research and Opinion, and Urologic Oncology.
Selected Publishing
-
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Journal of Medical Economics, 2024
2024Kaye DR, Khilfeh I, Muser E, Morrison L, Kinkead F, Urosevic A, Lefebvre P, Pilon D, George DJ
-
Economic Burden Associated With Nasal Polyposis Recurrence Among Commercially Insured Patients in the United States
Otolaryngology–Head and Neck Surgery, 2023
2023Zhdanava M, Ndife B, Pilon D, Rossi C, Vermette-Laforme M, Lefebvre P, Suh JD
-
Attainment of Early, Deep Prostate-Specific Antigen Response in Metastatic Castration-Sensitive Prostate Cancer: A Comparison of Patients Initiated on Apalutamide or Enzalutamide
Urologic Oncology, 2023
2023Lowentritt B, Pilon D, Khilfeh I, Rossi C, Muser E, Kinkead F, Waters D, Ellis L, Lefebvre P, Brown G
-
Comparison of Prostate-Specific Antigen Response in Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide or Abiraterone Acetate: A Retrospective Cohort Study
Urologic Oncology, 2023
2023Lowentritt B, Pilon D, Waters D, Rossi C, Muser E, Kurteva S, Shah A, Khilfeh I, Du S, Ellis L, Lefebvre P, Brown G
-
Ischemic Stroke and Systemic Embolism among One-and-Done Direct Oral Anticoagulant Users with Non-Valvular Atrial Fibrillation
Advances in Therapy, 2023
2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Treatment Patterns, Healthcare Utilization, and Costs of Patients with Treatment-Resistant Depression Initiated on Esketamine Intranasal Spray and Covered by Us Commercial Health Plans
Journal of Medical Economics, 2023
2023Joshi K, Pilon D, Shah A, Holiday C, Karkare S, Zhdanava M
-
Venous Thromboembolism Recurrence among One-and-Done Direct Oral Anticoagulant Users: A Retrospective Longitudinal Study
International Journal of Clinical Pharmacy, 2023
2023Alberts M, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Projecting the Economic Outcomes of Switching Patients with Schizophrenia from Oral Atypical Antipsychotics to Once-Monthly, Once-Every-3-Months, and Once-Every-6-Months Paliperidone Palmitate
Journal of Managed Care & Specialty Pharmacy, 2023
2023Morrison L, Lin D, Benson C, Ghelerter I, Vermette-Laforme M, Lefebvre P, Pilon D
-
Esketamine Nasal Spray for Major Depressive Disorder with Acute Suicidal Ideation or Behavior: Description of Treatment Access, Utilization, and Claims-Based Outcomes in the United States
Journal of Medical Economics, 2023
2023Zhdanava M, Teeple A, Pilon D, Shah A, Caron-Lapointe G, Joshi K
-
Treatment Persistence among Bio-Naïve Patients with Crohn's Disease Initiated on Ustekinumab or Adalimumab
Current Medical Research and Opinion, 2023
2023Zhdanava M, Ding Z, Manceur AM, Muser E, Lefebvre P, Holiday C, Lafeuille MH, Pilon D
-
Long-term persistence and other treatment patterns among bio-naïve patients with Crohn's disease treated with ustekinumab or adalimumab
Current Medical Research and Opinion, 2023
2023Zhdanava M, Ding Z, Manceur AM, Zhao R, Holiday C, Kachroo S, Izanec J, Pilon D
-
Persistence and Dose Escalation During Maintenance Phase and Use of Nonbiologic Medications Among Patients With Ulcerative Colitis Initiated on Ustekinumab in the United States
Crohn's & Colitis 360, 2023
2023Zhdanava M, Zhao R, Manceur AM, Kachroo S, Lefebvre P, Pilon D
-
Ischemic stroke and systemic embolism among patients with non-valvular atrial fibrillation who abandon oral anticoagulant therapy
Current Medical Research and Opinion, 2023
2023Alberts MJ, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Bookhart B, Kharat A
-
Access and real-world use patterns of esketamine nasal spray among patients with treatment-resistant depression covered by private or public insurance
Current Medical Research and Opinion, 2023
2023Teeple A, Zhdanava M, Pilon D, Caron-Lapointe G, Lefebvre P, Joshi K
-
Persistence and other treatment patterns among bio-experienced patients with Crohn's disease initiated on ustekinumab or adalimumab
Journal of Managed Care & Specialty Pharmacy, 2023
2023Zhdanava M, Zhao R, Manceur AM, Ding Z, Kachroo S, Holiday C, Lefebvre P, Pilon D
-
Continuity of care among patients newly initiated on second-generation oral or long-acting injectable antipsychotics during a schizophrenia-related inpatient stay
Current Medical Research and Opinion, 2023
2023Patel C, Pilon D, Morrison L, Holiday C, Lafeuille MH, Lefebvre P, Benson C
-
Persistence Among Patients with Crohn Disease Previously Treated with an Anti-tumor Necrosis Factor Inhibitor and Switching or Cycling to Another Biologic Agent
Clinical Therapeutics, 2023
2023Zhdanava M, Kachroo S, Manceur AM, Ding Z, Holiday C, Zhao R, Godwin B, Pilon D
-
Chronic corticosteroid use is associated with substantial clinical and economic burden in patients with Crohn's Disease initiated on biologic or conventional therapies in the US: A retrospective study
Journal of American Pharmacists Association, 2023
2023Zhdanava M, Zhao R, Manceur AM, Ding Z, Boudreau J, Kachroo S, Kerner C, Izanec J, Pilon D
-
Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States
Journal of Clinical Psychiatry, 2022
2022Pilon D, Neslusan C, Zhdanava M, Sheehan J, Joshi K, Morrison L, Rossi C, Lefebvre P, Greenberg P
-
Early prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide
Future Oncology, 2022
2022Bivins VM, Durkin M, Khilfeh I, Rossi C, Kinkead F, Waters D, Lefebvre P, Pilon D, Ellis L
-
Characteristics of Real-World Commercially Insured Patients With Treatment-Resistant Depression Initiated on Esketamine Nasal Spray or Conventional Therapies in the United States
Clinical Therapeutics, 2022
2022Karkare S, Zhdanava M, Pilon D, Nash AI, Morrison L, Shah A, Lefebvre P, Joshi K
-
Understanding the Health System Conditions Affecting the Use of Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia in Clinical Practice: A US Healthcare Provider Survey
Neuropsychiatric Disease and Treatment, 2022
2022Zhdanava M, Starr HL, Lefebvre P, Totev TI, Shah A, Sheng K, Pilon D
-
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
Journal of Medical Economics, 2022
2022Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C
-
Excess healthcare resource utilization and healthcare costs among privately and publicly insured patients with major depressive disorder and acute suicidal ideation or behavior in the United States
Journal of Affective Disorders, 2022
2022Zhdanava M, Voelker J, Pilon D, Joshi K, Morrison L, Sheehan JJ, Vermette-Laforme M, Lefebvre P, Citrome L
-
Real-World Prostate-Specific Antigen Response and Treatment Adherence of Apalutamide in Patients with Non-Metastatic Castration-Resistant Prostate Cancer
Urology, 2022
2022Lowentritt B, Brown G, Pilon D, Ellis L, Germain G, Rossi C, Lefebvre P, Kernen K, Sieber P, Shore N
-
Indicators of Suboptimal Treatment and Associated Healthcare Costs among Patients with Crohn's Disease Initiated on Biologic or Conventional Agents
Crohn's & Colitis 360, 2022
2022Pilon D, Ding Z, Muser E, Manceur AM, Vermette-Laforme M, Lafeuille MH, Lefebvre P
-
Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder
Current Medical Research and Opinion, 2021
2021Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Cluster Analysis of Care Pathways in Adults with Major Depressive Disorder with Acute Suicidal Ideation or Behavior in the USA
PharmacoEconomics (2021) 39:707–720
2021Zhdanava M, Voelker J, Pilon D, Cornwall T, Morrison L, Vermette‑Laforme M, Lefebvre P, Nash A, Joshi K, Neslusan C
-
The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
Journal of Clinical Psychiatry, 2021
2021Zhdanava M, Pilon D, Ghelerter I, Chow W, Joshi K, Lefebvre P, Sheehan JJ
-
Special Issue of PharmacoEconomics on Major Depressive Disorders
PharmacoEconomics (2021) 39:617
2021 -
Medication patterns of abiraterone acetate plus prednisone or enzalutamide and PSA progression in veterans with metastatic castration-resistant prostate cancer
Current Medical Research and Opinion, 2021
2021Freedland SJ, Li S, Pilon D, Bhak RH, Narkhede S, Lefebvre P, Young-Xu Y
-
Prevalence of Pre-existing Conditions Relevant for Adverse Events and Potential Drug-Drug Interactions Associated with Augmentation Therapies Among Patients with Treatment-Resistant Depression
Advances in Therapy, 2021
2021Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Economic burden in Medicaid beneficiaries with recently relapsed schizophrenia or with uncontrolled symptoms of schizophrenia not adherent to antipsychotics
Journal of Managed Care & Specialty Pharmacy, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Lefebvre P, Joshi K
-
Prevalence, incidence and economic burden of schizophrenia among Medicaid beneficiaries
Current Medical Research and Opinion, 2021
2021Pilon D, Patel C, Lafeuille MH, Zhdanava M, Lin D, Côté-Sergent A, Rossi C, Joshi K, Lefebvre P
-
Health care resource use, short-term disability days, and costs associated with states of persistence on antidepressant lines of therapy
Journal of Medical Economics, 2021
2021Pilon D, Karkare S, Zhdanava M, Sheehan JJ, Côté-Sergent A, Shah A, Lopena OJ, Lefebvre P, Joshi K, Citrome L
-
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions
Journal of Managed Care & Specialty Pharmacy, 2020
2020Zhdanava M, Kuvadia H, Joshi K, Daly E, Pilon D, Rossi C, Morrison L, Lefebvre P, Nelson C
-
Use of home health and other healthcare delivery pathways among privately-insured patients with and without treatment-resistant depression
Current Medical Research and Opinion, 2020
2020Pilon D, Szukis H, Singer S, Morrison L, Sheehan JJ, Lefebvre P
-
Costs associated with renal and cardiovascular events among patients with type 2 diabetes mellitus and nephropathy: a cost model based on the CREDENCE clinical trial
Current Medical Research and Opinion, 2020
2020Manceur AM, Durkin M, Kharat A, Bookhart B, Lafeuille MH, Pilon D, Fakih I, Lefebvre P
-
Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs
Journal of Medical Economics, 2020
2020Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P
-
Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia
Journal of Managed Care & Specialty Pharmacy, 2020
2020El Khoury AC, Pilon D, Morrison L, Shak N, Llaneza A, Kim E, Lefebvre P
-
Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer
Advances in Therapy, 2020
2020Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl AS, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA
-
US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
PharmacoEconomics - Open, 2020
2020Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P
-
Are Medicaid Coverage Gaps Associated with Higher Health Care Resource Utilization and Costs in Patients with Schizophrenia?
Population Health Management, 2020
2020Pilon D, El Khoury AC, Manceur AM, Zhdanava M, Benson C, Lefebvre P, Doshi JA
-
Matching-Adjusted Indirect Comparison of Health-Related Quality of Life and Adverse Events of Apalutamide Versus Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
Advances in Therapy, 2020
2020Chowdhury S, Oudard S, Uemura H, Joniau S, Pilon D, Lefebvre P, McQuarrie K, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J, Hadaschik BA
-
Prevalence of Potential Drug-Drug Interactions and Pre-existing Conditions for Adverse Events in Augmentation Therapies Among Patients With Treatment-resistant Depression
Psych Congress, 2020
2020Zhdanava M, Karkare S, Pilon D, Joshi K, Rossi C, Morrison L, Sheehan J, Lefebvre P, Lopena O, Citrome L
-
Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer
Urologic Oncology, 2020
2020Freedland SJ, Pilon D, Bhak RH, Lefebvre P, Li S, Young-Xu Y
-
Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans
Current Medical Research and Opinion, January 5, 2019
2019Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K
-
The economic burden of psoriasis with high comorbidity among privately insured patients in the United States
Journal of Medical Economics. 2019 Feb;22(2):196-203
2019Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P
-
Medicaid spending burden among beneficiaries with treatment-resistant depression
Journal of Comparative Effectiveness Research, February 8, 2019
2019Pilon D, Sheehan J, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE
-
The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia
Current Medical Research and Opinion. 2019 Mar;35(3):395-405
2019El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P
-
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records
Journal of Diabetes and its Complications, 2019
2019Wysham CH, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Ingham M
-
Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?
Journal of Affective Disorders, 2019
2019Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K
-
Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis
PLOS One, 2019
2019Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE
-
Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer
American Journal of Therapeutics, 2019
2019Pilon D, Ellis LA, Xiao Y, Behl AS, Lefebvre P
-
Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma
Clinical Therapeutics, 2019
2019Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, Ho H, Lefebvre P, Stone B
-
Long-term omalizumab outcomes in chronic idiopathic urticaria: a real-world study
Allergy & Asthma Proceedings, 2019
2019Kavati A, Zhdanava M, Ortiz B, LeCocq J, Schiffman B, Pilon D, Ching Cheung H, Lefebvre P, Stone BD
-
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials
Journal of Medical Economics, 2019
2019Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P
-
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate
PharmacoEconomics - Open, 2019
2019Emond B, Joshi K, El Khoury AC, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P
-
Real-world impact of glycated hemoglobin reduction on treatment intensification and glycated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i)
Current Medical Research and Opinion, 2019
2019Brunton S, Rozjabek HM, Pilon D, Lafeuille MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P
-
Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States
Dermatol Ther (Heidelb). Mar 2018;8(1):69-83
2018Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V
-
Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database
Journal of Clinical Psychiatry. Feb 20 2018;79(2)
2018Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE
-
Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting
Endocrine Practice. 03 2018;24(3):273-287
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting
Current Medical Research and Opinion. 2018 Jun;34(6):1125-1133
2018Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P
-
Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics
Current Medical Research and Opinion. Feb 28 2018:1-12.
2018Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K
-
Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin
Current Medical Research and Opinion. 2018 Jun;34(6):1099-1115
2018Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanava M, Emond B, Inman D, Bailey RA
-
Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma
Allergy and Asthma Proceedings. March-April 2018;39(2):127-135
2018Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B
-
Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States
Allergy and Asthma Proceedings. 2018 May 19;39(3):201-211
2018Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V
-
Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis
Current Medical Research and Opinion. 2018 Sep 5:1-9
2018Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P
-
Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab
Allergy & Rhinology, April 9, 2018
2018Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B
-
Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States
Allergy and Asthma Proceedings. 2018 May 7;39(3):191-200
2018Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA
-
Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk
Current Medical Research and Opinion. Apr 2017;33(4):631-638
2017Nelson WW, Laliberté F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P
-
Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program
Current Medical Research and Opinion. Apr 2017;33(4):713-721
2017Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ
-
Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide
Journal of Managed Care and Specialty Pharmacy. 2017;23(2):225-235
2017Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA
-
Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic
Patient Preference and Adherence. 22 Mar 2017;11:619-629
2017Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P
-
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors
BMC Endocrine Disorders. Jun 08 2017;17(1):32
2017Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS
-
A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on longacting mono-
International Journal of COPD. 21 Jun 2017;12:1825-1836
2017Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J
-
Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics
Journal of Medical Economics. Feb 2018; 21(2):135-143
2017Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C
-
Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy
American Health and Drug Benefits. 2017;10(3):143-152
2017Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA
-
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics
Clinical Therapeutics. Oct 2017;39(10):1972-1985 e1972
2017Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K
-
Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics
Current Medical Research and Opinion, 2016 04; 32(4): 759-769. e-pub ahead of print 2016/01/12
2016Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.
-
Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy
Menopause, 2016 06; 23(6): 600-610
2016Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.
-
Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population
Reproductive Health, 2016 13(1): 96. e-pub ahead of print 2016/08/24
2016Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.
-
Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.
Current Medical Research and Opinion, Opin 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27
2016Lefebvre P, Pilon D, Robitaille MN, Lafeuille MH, Chow W, Pfeifer M, Duh MS.
-
Hospital length of stay of nonvalvular atrial fibrillation
Hospital Practice, August 2014, Vol. 42, No. 3
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, August 2014, Vol. 30, No. 8
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
Current Medical Research & Opinion, July 2014, Vol. 30, No. 7
2014Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P
-
Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Current Medical Research & Opinion, April 2014, Vol. 30, No. 4
2014Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P
-
Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost
Journal of Medical Economics, December 2014, Vol. 17, No. 12
2014Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A
News
-
January 29, 2024
-
October 23, 2023
-
March 2, 2023
-
April 12, 2022
-
March 29, 2022
-
October 15, 2021
-
June 14, 2021
-
June 10, 2021
-
June 8, 2021
-
January 21, 2021